# Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid Leukemia

> **NCT06652685** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 218 (estimated)

## Conditions studied

- Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** D5-PBCR(-) IA arm
- **DRUG:** D5-PBCR(+) IA+Venetoclax arm

## Key facts

- **NCT ID:** NCT06652685
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10-30
- **Primary completion:** 2026-10-31
- **Final completion:** 2027-06-30
- **Target enrollment:** 218 (ESTIMATED)
- **Last updated:** 2024-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06652685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06652685, "Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06652685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*